351006APC antihuman CD276 B7H3 MIH42 100T and 3 more items

Virginia Commonwealth University has awarded BioLegend a contract valued at $1,124.55 effective August 27, 2026. The contract covers the procurement of specialized laboratory reagents and antibodies for delivery to Virginia Commonwealth University Procurement. The deliverables consist of four distinct line items: an anti-human CD276 B7H3 monoclonal antibody (MIH42, 100 test unit) priced at $219.80; a Fire 750 anti-human CD45RA fluorescent antibody (HI100, 100 test unit) at $259.00; a Brilliant Violet 510 anti-human CD117 conjugate at $311.25; and a Brilliant Violet 605 anti-human CD326 EpCAM conjugate at $334.50. Each line item represents a single unit purchase delivered to Virginia Commonwealth University's procurement office.

These reagents are classified as specialized immunological research materials, with applications in flow cytometry and cellular research. The contract fulfills Virginia Commonwealth University's requirement for fluorescently conjugated monoclonal antibodies targeting specific cell surface antigens, enabling researchers to identify and analyze distinct cell populations in biological samples. The cumulative contract value of $1,124.55 reflects a small-scale procurement of research-grade laboratory supplies in support of Virginia Commonwealth University's scientific research operations within the Commonwealth of Virginia.